Abstract

Obat-obatan palsu berpotensi mencapai 70% dari pasaran obat internasional dengan proporsi terbanyak ditemukan di negara berkembang. Meningkatkan kesadaran masyarakat akan adanya obat-obatan palsu akan secara langsung memengaruhi permintaan produk obat palsu yang akhirnya akan mengurangi kegiatan pemalsuan obat. Akan tetapi, meningkatkan pengetahuan masyarakat akan bahaya obat-obatan palsu tidaklah mudah sebab profesi kesehatan masyarakat harus juga mempertimbangkan keberagaman faktor-faktor sosial, ekonomi dan pendidikan. Laporan ini menelaah artikel jurnal yang ditelaah oleh kelompok seminat, laporan media, laporan resmi pemerintah dan non-pemerintah. Sebanyak 179 artikel (dari 1990 sampai 2014) ditelaah untuk mengetahui hubungan antara indeks pembangunan manusia (IPM) dari USA, Jepang, Brasil, Iran, Vietnam, Indonesia, Pakistan dan Nigeria, dan tipe pemalsuan obat. Pencarian elektronik menggunakan pangkalan data seperti Medline, Scopus, CINAHL, Embase, Google Scholar. Obat-obatan palsu untuk pengobatan ditemukan dalam banyak ragam terutama di negara dengan IPM rendah. Pada saat yang sama, obat-obatan untuk keperluan gaya hidup tidak hanya ditemukan di negara dengan IPM tinggi, akan tetapi juga beredar di negara dengan IPM rendah dan sedang. Counterfeit medicines potentially reach 70% of the global drug markets, and the largest proportion is found in developing countries. Increasing public awareness of counterfeit medicines will automatically affect the demand for counterfeit medical products that will finally reduce counterfeit medicine activities. However, raising awareness of the dangers of counterfeit medicines is a challenging task because public health professionals need to consider diversity of social, economic and educational factors. This study examined peer-reviewed journal articles, media reports, official government and non-government reports. As many as 179 papers (1990 to 2014) were retrieved to identify the relationship between Human Development Index (HDI) of the USA, Japan, Brazil, Iran, Vietnam, Indonesia, Pakistan and Nigeria, and the type of counterfeit medicines. An electronic search was conducted using the following databases, such as Medline, Scopus, CINAHL, Embase, Google Scholar. Counterfeit disease curing medicines are found in high varieties most likely in countries with low HDI. At the same time, medicines for lifestyle are not solely found in countries with high HDI, but also exist in low to medium HDI.

References

1. World Health Organization. WHO | Growing threat from counterfeit medicines. Bulletin WHO. 2011 [cited September 2016] ; 88 (10): 1-3. Available from: http://www.who.int/bulletin/volumes/88/4/10- 020410/en/.

2. World Health Organization. WHO launces taskforce to fight counterfeit drugs. Bulletin WHO. 2006 [cited September 2016]; 84 (9): 1-8. Available from: http://www.who.int/bulletin/volumes/84/9/news.pdf

3. World Health Organization. Report of the situation of counterfeit medicines based on data collection tool. WHO Regions for Africa and Eastern Mediterranean. A World Health Organization Resource. 2010 [cited September 2016). Available from: http://apps.who.int/medicinedocs/en/d/Js18385en/. Published 2010.

4. Raufu A. India agrees to help Nigeria tackle the import of fake drugs. British Medical Journal. 2003 [cited November 2016]; 326 (7401). Available from: http://www.bmj.com/content/326/7401/1234.4.

5. Clift C. Combating counterfeit, falsified and substandard medicines: defining the way forward? | Chatham House. Briefing paper. Center of Global Security United Kingdom. 2010 [Cited November 2016]:6. Available from: https://www.chathamhouse.org/publications/papers/ view/109517.

6. World Health Organization. Affordable medicines for developing countries : pills and pocket book. Geneva: World Health Organization; 2000 [cited September 2016]. Available from : http://www.who.int/medicines/areas/access/OMS_Medicine_prices.pdf.

7. Akunyili D. Lessons from Nigeria?: the fight against counterfeit drugs in Africa. Diabetes Society Journal. 2006 [cited September 2016]; 51 (3): 41-55. Available from: http://apps.who.int/medicinedocs/documents/s18404en/s18404en.pdf

8. Amin AA, Kokwaro GO. Antimalarial drug quality in Africa. Journal Clinical Pharmacology Therapy. 2007 [cited September 2016]; 32 (5): 429-40. Available from: https://www.ncbi. nlm.nih.gov/pmc/articles/ PMC2653781/

9. Glass BD. Counterfeit drugs and medical devices in developing countries: Study report. Tropical medicine Journal. 2014 [cited October 2016]; 5: 11-22. Available from : http://studyonline.jcu.edu.au/33198/

10. Pullirsch D, Bellemare J, Hackl A, Trottier YL, Mayrhofer A, Schindl H, et al. Microbiological contamination in counterfeit and unapproved drugs. British Medical Pharmacology and Toxicology Journal. 2014 [cited November 2017]; 15: 34. Available from : https://www.ncbi.nlm. nih.gov/pubmed/24965483.

11. US Food and Drug Administration. Counterfeit drugs: fighting illegal supply chains. US Food and Drugs Administration. 2014 [cited September 2016]. Available from: https://www.fda.gov/newsevents/testimony/ ucm387449.htm. Published 2014.

12.Wold Health Organizations. WHO launches taskforce to fight counterfeit drugs. Bulletin World Health Organization. 2011 [cited December 2016]; 84(9): 2-7. Available from: http://www.who.int/bulletin/volumes/84/9/06-010906/en/.

13. Spink J, Moyer D. Understanding food and combating fraud. Food Technology Magazine USA. 2013 [cited September 2016]; 67: 30-35. Available from: http://foodfraud.msu.edu/wp-content/uploads/2013/03/Article-Understanding-and-Combating-Food-Fraud-FTFood-Technology-2013-01-b.pdf.

14. Moyer D, Spink J. Defining public health threat of food fraud. Food science Journal. 2011 [cited September 2016]; 76: 157-63. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22416717

15. Davidson M. Medicine Anti-counterfeiting: Government issue. London: John Wiley and sons Ltd; 2011.

16. Laeny R. Anjuran dari Kemenkes agar terhindar obat palsu | Republika Online. Republika [cited September 2016]. Available from : http://nasional.republika.co.id/berita/nasional/umum/14/11/27/nfpbyl-anjurandari-kemenkes-agar-terhindar-obat-palsu.

17. Spink J. Product fraud and product counterfeiting as a source of terrorist financing. Security Journal. 2015 [cited November 2016]; 19: 72. Available from : http://foodfraud.msu.edu/2015/02/27/publicationproduct-fraud-and-product-counterfeiting-as-a-source-of-terrorist-financing/

18. Blackstone EA, Fuhr JP, Pociask S. The health and economic effects of counterfeit drugs. American Healing drug benefits journal. 2014 [cited October 2016]; 7 (4): 216-24. Available from: http://www.ncbi. nlm.nih.gov/pubmed/25126373.

19. Hartley D. Rural health disparities, population health, and rural culture. American Journal Public Health. 2004 [cited October 2016]; 94 (10): 1675-8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/ 15451729.

20. Dégardin K, Roggo Y, Margot P. Forensic intelligence for medicine anti-counterfeiting. Forensic Scencei International journal. 2015 [cited November 2016]; 248: 15-32. Available from: https://www.ncbi.nlm. nih.gov/pubmed/25576676.

21. Ian CD. Systematic reviews. British Medical Journal Publishing Group; 1995.

22. United Nations Development Programme. Human development reports. United Nations Development Programme. 2016 [cited September 2016]. Available from : http://hdr.undp.org/en/composite/HDI. Published 2016.

23. International Medical Product Anticounterfeiting Taskforce (IMPACT): an update on estimates. International Medical Product Anticounterfeiting Taskforce. 2006 [cited December 2016]. Available from: http://apps.who.int/medicinedocs/en/d/Js20967en/

24. Hosseini SAR, Darbooy S, Tehrani Banihashemi SA, Naseri SM, Dinarvand R. Counterfeit medicines: Report of a cross-sectional retrospective study in Iran. Public Health Journal Iran. 2011; 125 (3): 165- 71.

25. Ames J, Souza DZ. Falsificação de medicamentos no Brasil. Review Saude Publica Journal. 2012 [cited November 2016]; 46 (1): 154-9. Available from: http://www.scielo.br/scielo.php?pid=S003489 102012000100019&script=sci_arttext&tlng=en

26. Japan Medicine Manufacture Medicines (JPMA). Countermeasures against counterfeit medicines. Japan Medicine Manufacture Medicines. 2015 [cited Decmeber 2016]. Available from: http://www. jpma.or.jp/english/globalhealth/fake_measures/about_fake_measures.html

27. Pfizer. A serious threat to patient safety. Counterfeit medicines. Pfizer global security 2007 [cited November 2016]. Available from : http://www.pfizer.com/files/products/CounterfeitBrochure.pdf.

28. US Food and Drug Administration [Homepage on Internet]. Counterfeit medicines. Official website of US Food and Drug Administration 2016 [cited November 2016]. Available from : http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsing MedicineSafely/CounterfeitMedicine/

29. Punjab. Fake medicine: Unofficial death toll reaches 112 - The Express Tribune. Express Tribune. 2012 [cited September 2016]: 1. Available from : https://tribune.com.pk/story/328886/fake-medicine-unofficialdeath-toll-reaches-111/.

30. Nablus M. Palestinian police continue seizure of expired and counterfeit cosmetics, drugs and detergents. Maan News Agency. 2009 [cited September 2016]: 2. Available from: http://www.maannews.com/ Content.aspx?id=209799.

31. Zofeen I. Unregulated drug market has deadly impact in Pakistan | Inter Press Service. Interpress service [cited December 2016]. Available from : http://www.ipsnews.net/2012/12/unregulated-drug-market-has-deadly-impact-in-pakistan/.

32. International Institute of Study Agains Counterfeit Medicine (IRACM). 13 held in PIC drugs scandal Iran. 2012 [cited December 2016]. Available from : http://www.iracm.com/en/2012/03/13-held-in-picdrugs-scandal/.

33. Milissa M. Media reports on medicine quality: Focusing on USAID-assisted countries. United States Agency for International Development. 2013 [cited November 2016]. Available from: http:// www.usp.org/sites/default/files/usp_pdf/EN/PQM/media_reports2013-august.pdf.

34. Sauwakon R, Souly P. The state of medicine quality in the Mekong subregion in the 2000s and the challenges ahead. Institut de Recherche sur l’Asie du Sud-Est Contemporaine Study Institute on Contemporary Southeast Asia. 2015 [cited November 2016]. Available from : http://www.irasec.com/ouvrage115.

35. Badan Pengawas Obat dan Makanan. Laporan tahun 2015. Jakarta: Badan Pengawas Obat dan Makanan; 2015 [cited September 2016]. Available from : http://www.pom.go.id/new/index.php/browse/laporan_tahunan/20-04-2007/20-04-2017/1. Published 2015.

36. Daly MC, Duncan GJ, McDonough P, Williams DR. Optimal indicators of socioeconomic status for health study. America Journale Public Health. 2002 [cited November 2016]; 92 (7): 1151-7. Available from : http://www.ncbi.nlm.nih.gov/pubmed/12084700.

37. Food and Drugs Administration. Drug supply chain integrity - Issues letters to doctors who may have purchased counterfeit or unapproved prescription drugs. US Food and Drugs Administration. [2016] [cited November 2016]. Available from: https://www.fda.gov/Drugs/ DrugSafety/DrugIntegrityandSupplyChainSecurity/ucm439169.htm.

38. Catarina F. Country report: The healthcare market in Japan. PM Group Worldwide Limited; 2012 [cited November 2016]. Available from : http://www.pmlive.com/pharma_intelligence/country_report_the_healt hcare_market_in_japan_379354.

39. John PG, John P, Geoffrey R. Medicines medicines. London: John Wiley and sons Ltd; 2012.

40. Bankole S. Piracy and counterfeiting: Gatt trips and developing countries: International economic development law. Medicines Medicines. New York: Springer publisher; 1997.

41. Buckley GJ, Gostin LO. The effects of falsified and substandard drugs. USA: National Academies Press (US); 2013 [cited September 2016]. Available from : https://www.ncbi.nlm.nih.gov/books/NBK202526/.

42. Albert L PW. Counterfeit medicines?: Policy, economics, and countermeasures. United Kingdom: ILM Publications; 2012.

43. Bansal D, Malla S, Gudala K, Tiwari P. Anti-counterfeit technologies: a medicine industry perspective. Science Medicines journal. 2013 [cited October 2016)]; 81 (1): 1-13. Available from: https://www.ncbi. nlm.nih.gov/pmc/articles/PMC3617666/.

44. Royal Medicines Society of Great Britain. Counterfeit medicines advice for healthcare professionals: Guidance for pharmacist and dispensing Doctors. United Kingdom: Medicine and Healthcare Product Agency; 2009 [cited September 2016]. Available from: https://www.fip.org/ files/fip/counterfeit/national/UKCounterfeitadvice209.pdf

45. Gibson L. Drug regulators study global treaty to tackle counterfeit drugs. British Medical Journal. 2004 [cited November 2016]; 328 (7438). Available from: http://www.bmj.com/content/328/7438/ 486.4.

46. International Medical Product Anti-Counterfeiting Taskforce. Counterfeit medicines: an update on estimates. World Health Organization. (cited November 2016) Available from: http:// www.who.int/medicines/services/counterfeit/impact/TheNewEstimates Counterfeit.pdf.

47. Morris J, Stevens P. Counterfeit medicines in less developed countries Problems and solutions about International Policy Network. In:International Policy Network.; 2006 [cited November 2016]: 1-9.. Available from: http://zuckermanfellows.harvard.edu/index.php/content/download/70550/1255010/version/1/file/Morris_Stevens.pdf

48. International Institute of StudyAgains Counterfeit Medicine (IRACM). Prevention against global trafficking of counterfeit drugs. International Institute of StudyAgains Counterfeit Medicine. [cited December 2016]. Available from: http:// www.iracm.com/en/commitment-and-strategy/prevention/.

Download

Share

COinS